{
    "2020-11-02": [
        [
            {
                "time": "2018-11-02",
                "original_text": "格隆汇港股聚焦(11.2)︱中国奥园10月合同销售额同比增51%；富力地产前10个月销售额1026亿元",
                "features": {
                    "keywords": [
                        "中国奥园",
                        "合同销售额",
                        "同比增51%",
                        "富力地产",
                        "销售额1026亿元"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "房地产"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-03",
                "original_text": "A股头条之上市公司（11.3）",
                "features": {
                    "keywords": [],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-11-02",
                "original_text": "上海医药(02607.HK)：头孢氨苄胶囊通过仿制药一致性评价",
                "features": {
                    "keywords": [
                        "上海医药",
                        "头孢氨苄胶囊",
                        "仿制药一致性评价"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-02",
                "original_text": "【国信医药】上海医药：研发加码持续，创新开花可期（三季报点评）",
                "features": {
                    "keywords": [
                        "上海医药",
                        "研发加码",
                        "创新开花",
                        "三季报点评"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-02",
                "original_text": "交银国际：上海医药维持买入评级 目标价17.87港元",
                "features": {
                    "keywords": [
                        "交银国际",
                        "上海医药",
                        "买入评级",
                        "目标价17.87港元"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-02",
                "original_text": "上海医药(601607)：商业板块加速恢复 持续加码研发创新",
                "features": {
                    "keywords": [
                        "上海医药",
                        "商业板块",
                        "加速恢复",
                        "加码研发创新"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}